2 results
Approved WMOCompleted
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Approved WMOCompleted
To determine if aspiration thrombectomy can reduce the rate of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or new or worsening NYHA Class IV heart failure in patients with STEMI undergoing primary PCI.